Missed the webinar? Here are Investing.com’s top 10 stock picks for 2026
Director Isaac Paul J of Stereotaxis , Inc. (NASDAQ:STXS) recently purchased shares of the company’s common stock in two transactions, totaling $66,600. The insider buying comes as InvestingPro data shows the stock has fallen over 25% in the past week, with shares currently trading at $2.27.
On November 14, 2025, Isaac acquired 20,000 shares at a price of $2.24 per share. Three days later, on November 17, 2025, he purchased an additional 10,000 shares at $2.18 per share. Following these transactions, Isaac directly owns 97,299 shares and indirectly owns 2,786,557 shares.This insider buying occurs while InvestingPro indicates the stock is in oversold territory, with analyst price targets ranging from $4 to $5 per share, suggesting significant upside potential. Despite the company’s weak financial health score and negative earnings forecast, this director appears confident in Stereotaxis’s future prospects. Discover more insights with the comprehensive Pro Research Report available for this medical technology company.
In other recent news, Stereotaxis Inc. announced its Q3 2025 earnings, reporting a revenue of $7.5 million. This figure was below the anticipated $8.38 million, marking a shortfall of approximately 10.98%. The company’s earnings per share (EPS) was reported at -$0.07, which was slightly lower than the projected -$0.06, resulting in a 16.67% surprise. Despite missing revenue forecasts, these developments have sparked investor interest, as reflected in the company’s stock performance. The results highlight the challenges Stereotaxis faces in meeting financial expectations. However, the market’s reaction suggests a focus on potential strategic developments. Investors and analysts will be closely monitoring how Stereotaxis navigates these financial results moving forward.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.